Alumis ALMS
Alumis Q2 FY26: revenue $1.7M, down 38%; diluted EPS −$1.11
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001847367-26-000018
Key figures from this report
These are the numbers Alumis reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$1.7M−38% from $2.7M in Q2 FY2510-Q income statement, on EDGAR
- Net income−$142.2M−340% from $59.3M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS−$1.11−244% from $0.77 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$63.7M−58% from $151.8M in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations−$81.5MAgainst −$106.4M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Crescent Biopharma CBIO public float $177M, Jun 30, 2025
- Editas Medicine EDIT public float $191M, Jun 30, 2025
- Omeros OMER public float $172M, Jun 30, 2025
- Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
- Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
